Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported results from a planned interim analysis of the company’s multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. According to the interim analysis the safety profile was similar between the treatment and placebo arms.
Based on a composite efficacy endpoint assessing time to treatment failure (including major amputations, wound size and gangrene), Aastrom’s autologous vascular repair cells (VRCs) were more effective than placebo (P<0.05). Other clinically meaningful endpoints (e.g., major amputation rate, complete wound closure) approached but did
Stem Cell Research Study Reveals Stroke Patients Helped by Own Stem Cells
A new stem cell research study/trial recently completed shows that implanting a person’s own Adult Stem Cells helps stroke patients overcome partial paralysis. Dr. Kameshwar Prasad of the All India Institute of Medical Sciences (AIIMS) will present his stem cell study […]
Image via Wikipedia
Scientists have made a breakthrough in stem cell research which raises the prospect of regrowing damaged sections of a person’s liver, pancreas or even their brain.
Researchers at the University of NSW have found a way to improve the lifespan and competitiveness of stem cells, overcoming a problem which otherwise saw their regenerative powers fade in about an hour.
Adult stem cells were given a gene to make them resistant to chemotherapy, handing them an “advantage” when used to treat damaged tissue in conjunction with the cancer-fighting treatment.
University of NSW Professor Peter Gunning said as the chemotherapy cleaned out
SANUWAVE Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled “Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells” were presented at the 2009 International Bone-Tissue-Engineering Congress (“Bone-Tec”) in Hannover, Germany, which was held October 9-11, 2009.
Dr. Myron Spector, PhD, Professor of Orthopaedic Surgery (Biomaterials) at Harvard Medical School, Director of Orthopaedic Research at Brigham and Women’s Hospital and Director of Tissue Engineering at VA Boston Healthcare System, was an invited guest speaker at the Conference. The
Image via Wikipedia
It works in racehorses. Who knows if it’s possible in humans. A technique using stem cells to repair damage to the Achilles tendon is about to be tested in Great Britain.
British biotech company MedCell Bioscience has announced that it will begin human testing in the next six months and expects to perform a broad study in various European hospitals in 2011.
Patients will receive injections containing millions of their own stem cells extracted and multiplied in the lab to regenerate damaged tissue. Over 1,500 racehorses have been treated with the same procedure and the results